Horizon Therapeutics plc Named Title Partner of the Irish Open
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Horizon Therapeutics (HZNP) PT Raised to $145 at BMO Capital
February 14, 2022 6:57 AM ESTBMO Capital analyst Gary Nachman raised the price target on Horizon Therapeutics (NASDAQ: HZNP) to $145.00 (from $138.00) while maintaining an Outperform rating.
The analyst commented, "4Q21 should be solid with HZNP recently reaffirming guidance for key products, and Tepezza "whisper" expectation should be more... More
